Business Description
Pharmaron Beijing Co Ltd
ISIN : CNE100003PG4
Share Class Description:
FRA:17Q1: Ordinary Shares - Class HTotal Employee Number:
25,088Compare
Compare
Traded in other countries / regions
300759.China03759.Hong Kong17Q1.GermanyPHBBF.USA IPO Date
2019-12-30Description
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.42 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.43 | |||||
Debt-to-EBITDA | 3.28 | |||||
Interest Coverage | 11.35 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.55 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.2 | |||||
3-Year EBITDA Growth Rate | 9.2 | |||||
3-Year EPS without NRI Growth Rate | 2.8 | |||||
3-Year Book Growth Rate | 12.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.44 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 16.01 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.26 | |||||
9-Day RSI | 64.36 | |||||
14-Day RSI | 67.07 | |||||
3-1 Month Momentum % | -18.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.08 | |||||
Quick Ratio | 0.88 | |||||
Cash Ratio | 0.36 | |||||
Days Inventory | 53.79 | |||||
Days Sales Outstanding | 63.42 | |||||
Days Payable | 21.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1 | |||||
Dividend Payout Ratio | 0.2 | |||||
3-Year Dividend Growth Rate | -12.6 | |||||
Forward Dividend Yield % | 1 | |||||
5-Year Yield-on-Cost % | 2.6 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | -0.66 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 34.51 | |||||
Operating Margin % | 15.61 | |||||
Net Margin % | 11.62 | |||||
EBITDA Margin % | 14.84 | |||||
FCF Margin % | 1.9 | |||||
OCF Margin % | 20.34 | |||||
ROE % | 11.38 | |||||
ROA % | 6.47 | |||||
ROIC % | 8.21 | |||||
3-Year ROIIC % | 4.29 | |||||
ROC (Joel Greenblatt) % | 16.62 | |||||
ROCE % | 10.83 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 40.47 | |||||
Forward PE Ratio | 17.92 | |||||
PE Ratio without NRI | 39.97 | |||||
Shiller PE Ratio | 61.26 | |||||
PEG Ratio | 2.96 | |||||
PS Ratio | 4.72 | |||||
PB Ratio | 4.3 | |||||
Price-to-Tangible-Book | 6 | |||||
Price-to-Free-Cash-Flow | 243.86 | |||||
Price-to-Operating-Cash-Flow | 23.1 | |||||
EV-to-EBIT | 31.94 | |||||
EV-to-Forward-EBIT | 24.72 | |||||
EV-to-EBITDA | 31.94 | |||||
EV-to-Revenue | 4.74 | |||||
EV-to-Forward-Revenue | 4.16 | |||||
EV-to-FCF | 246.5 | |||||
Price-to-GF-Value | 1.16 | |||||
Price-to-Projected-FCF | 4.87 | |||||
Price-to-DCF (Earnings Based) | 0.72 | |||||
Price-to-DCF (FCF Based) | 11.73 | |||||
Price-to-Peter-Lynch-Fair-Value | 5.73 | |||||
Price-to-Graham-Number | 3.27 | |||||
Earnings Yield (Greenblatt) % | 3.13 | |||||
FCF Yield % | 0.44 | |||||
Forward Rate of Return (Yacktman) % | 7.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pharmaron Beijing Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,774.733 | ||
| EPS (TTM) (€) | 0.115 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 67.07 | ||
| 14-Day ATR (€) | 0.058716 | ||
| 20-Day SMA (€) | 2.385 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 1.6 - 2.74 | ||
| Shares Outstanding (Mil) | 1,837.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pharmaron Beijing Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pharmaron Beijing Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-28 | In 94 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 26 days | ||
| HKD 0.229927 Cash Dividend | 2026-07-07 | 2.24 (+0.00%) | ||
| General meeting for 2025 | 2026-06-12 13:30 | 1.61 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 2.32 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 1.98 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-10-28 | -- | ||
| Second quarter earnings results for 2025 | 2025-08-21 | -- | ||
| HKD 0.218771 Cash Dividend | 2025-07-04 | -- | ||
| General meeting for 2024 | 2025-06-20 13:30 | -- |
Show
Entries
Pharmaron Beijing Co Ltd Frequently Asked Questions
What is Pharmaron Beijing Co Ltd(FRA:17Q1)'s stock price today?
The current price of FRA:17Q1 is €2.58. The 52 week high of FRA:17Q1 is €2.74 and 52 week low is €1.60.
When is next earnings date of Pharmaron Beijing Co Ltd(FRA:17Q1)?
The next earnings date of Pharmaron Beijing Co Ltd(FRA:17Q1) is 2026-08-21 Est..
Does Pharmaron Beijing Co Ltd(FRA:17Q1) pay dividends? If so, how much?
The Dividend Yield %  of Pharmaron Beijing Co Ltd(FRA:17Q1) is 1% (As of Today), Highest Dividend Payout Ratio of Pharmaron Beijing Co Ltd(FRA:17Q1) was 0.38. The lowest was 0.14. And the median was 0.23. The  Forward Dividend Yield % of Pharmaron Beijing Co Ltd(FRA:17Q1) is 1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Pharmaron Beijing Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers